<DOC>
	<DOCNO>NCT01621321</DOCNO>
	<brief_summary>This research project evaluate efficacy safety two different treatment protocol Allergic bronchopulmonary Aspergillosis .</brief_summary>
	<brief_title>Voriconazole Versus Oral Steroids Allergic Bronchopulmonary Aspergillosis</brief_title>
	<detailed_description>Allergic bronchopulmonary aspergillosis ( ABPA ) pulmonary disorder cause complex hypersensitivity response antigen release fungus Aspergillus fumigatus . The management ABPA include two important aspect - institution immunosuppressive therapy form glucocorticoid control immunologic activity , close monitoring detection relapse . Another possible target use antifungal agent attenuate fungal burden secondary fungal colonization airway . Oral corticosteroid currently treatment choice ABPA associate bronchial asthma.They suppress immune hyperfunction also anti-inflammatory . However , data guide dose duration glucocorticoid different regimen glucocorticoid use literature.Itraconazole , oral triazole relatively low toxicity , active Aspergillus spp . vitro vivo . The activity itraconazole Aspergillus spp . ketoconazole . The administration itraconazole eliminate Aspergillus airway theoretically reduce allergic response ABPA . The new triazoles , voriconazole , recently find effective treatment fungal infection . The investigator hypothesize voriconazole might also useful treatment ABPA . The aim prospective randomize control trial ( RCT ) evaluate efficacy safety voriconazole therapy patient ABPA .</detailed_description>
	<mesh_term>Aspergillosis</mesh_term>
	<mesh_term>Pulmonary Aspergillosis</mesh_term>
	<mesh_term>Aspergillosis , Allergic Bronchopulmonary</mesh_term>
	<mesh_term>Voriconazole</mesh_term>
	<mesh_term>Prednisolone acetate</mesh_term>
	<mesh_term>Methylprednisolone acetate</mesh_term>
	<mesh_term>Prednisolone</mesh_term>
	<mesh_term>Methylprednisolone</mesh_term>
	<mesh_term>Methylprednisolone Hemisuccinate</mesh_term>
	<mesh_term>Prednisolone hemisuccinate</mesh_term>
	<mesh_term>Prednisolone phosphate</mesh_term>
	<criteria>Presence follow three criterion : Immediate cutaneous hyperreactivity aspergillus skin test Elevated total IgE level &gt; 1000 IU/mL A fumigatus specific IgE level &gt; 0.35 kUA/L And , two follow criterion : Presence serum precipitate antibody A fumigatus Fixed transient radiographic pulmonary opacity Total eosinophil count &gt; 1000/ÂµL Central bronchiectasis HRCT Failure give informed consent Intake glucocorticoid three week precede six month Enrollment another trial ABPA Any exposure azoles last six month</criteria>
	<gender>All</gender>
	<minimum_age>15 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>January 2017</verification_date>
</DOC>